 |
|
|
| |
Safety and Preliminary Efficacy of the Farnesoid X
Receptor Agonist Cilofexor in a 96-week Open-label
Extension of a Phase 2 Study of PSC
|
| |
| |
AASLD 2021 Nov 12-15
Michael Trauner,1 Aliya Gulamhusein,2 Bilal Hameed,3 Stephen H. Caldwell,4 Mitchell L. Shiffman,5 Charles Landis,6 Andrew J. Muir,7 Jun Xu,8 Xiaomin Lu,8 Chuhan Chung,8 Robert P. Myers,8 Christopher L. Bowlus,9 Kris V. Kowdley10
1Medical University of Vienna, Vienna, Austria; 2University of Toronto, Toronto, ON, Canada; 3University of California, San Francisco School of Medicine, San Francisco, CA; 4University of Virginia, Charlottesville, VA; 5Bon Secours Liver Institute, Richmond, VA; 6University of Washington School of Medicine, Seattle, WA; 7Duke University School of Medicine, Durham, NC;
8Gilead Sciences, Inc., Foster City, CA; 9University of California Davis, Davis, CA;
10Liver Institute Northwest, Seattle, WA
|
| |
|
|
|
|
|
